RESUMO
Coagulation factor XIII (FXIII) is a fibrin-stabilizing factor with additional roles in wound healing and interactions between the decidua and fetus. Congenital FXIII deficiency is rare bleeding disorder. Inhibitor development against FXIII in inherited FXIII deficency is also uncommon, but may cause severe, life-threatening bleeding. FXIII is the last step in the coagulation cascade with normal coagulation paramaters (PT, aPTT), the detection of inhibitor to FXIII is quite difficult. The treatment of inhibitor-positive congenital FXIII deficiency is challenging due to the lack of a role of by-pass agents such as FVII. The best known ways of treatment in these cases are the use of high-dose FXIII concentrates and immunosuppression. Herein, we report the management of postoperative bleeding diathesis in a patient with FXIII deficiency who developed inhibitors, and to follow the clinical course of the disease with FXIII concentrate and immunosuppression.
Assuntos
Anticorpos Neutralizantes/imunologia , Inibidores dos Fatores de Coagulação Sanguínea/sangue , Deficiência do Fator XIII/complicações , Fator XIII/antagonistas & inibidores , Transtornos Hemorrágicos/tratamento farmacológico , Imunossupressores/uso terapêutico , Isoanticorpos/sangue , Inibidores dos Fatores de Coagulação Sanguínea/imunologia , Criança , Fator XIII/imunologia , Transtornos Hemorrágicos/etiologia , Transtornos Hemorrágicos/patologia , Humanos , Masculino , PrognósticoRESUMO
Coagulation factor XIII is a fibrin-stabilizing factor that leads to the crosslinking of fibrin when activated by thrombin. Acquired factor XIII inhibitor is caused when antibodies are generated against factor XIII, reducing its activity. Here we report a case of acquired factor XIII inhibitor. Although prednisolone was administered, factor XIII activity was not recovered. Interestingly, the activity normalized following the onset of multiple myeloma. The presence of inhibitors was evaluated in the patient's plasma by absorption tests and enzyme-linked immunosorbent assay. Immunoglobulin G inhibitors of factor XIII were present at admission, but later decreased with the onset of the IgA-λ-type myeloma. Thus, it is possible that the level of factor XIII inhibitors and polyclonal immunoglobulins could have been suppressed by the progression of myeloma, resulting in the normalization of factor XIII activity.
Assuntos
Deficiência do Fator XIII , Imunoglobulina A , Mieloma Múltiplo , Remissão Espontânea , Fator XIII/imunologia , HumanosAssuntos
Afibrinogenemia/sangue , Afibrinogenemia/diagnóstico , Fator XIII/metabolismo , Afibrinogenemia/etiologia , Afibrinogenemia/terapia , Biomarcadores , Coagulação Sanguínea , Testes de Coagulação Sanguínea , Ativação Enzimática , Terapia de Reposição de Enzimas , Fator XIII/imunologia , Fibrinogênio/administração & dosagem , Fibrinogênio/efeitos adversos , Fibrinogênio/uso terapêutico , Humanos , Resultado do TratamentoAssuntos
Deficiência do Fator XIII/diagnóstico , Fator XIII/metabolismo , Hemorragia/diagnóstico , Imunossupressores/uso terapêutico , Ácido Micofenólico/uso terapêutico , Idoso de 80 Anos ou mais , Animais , Anticorpos Neutralizantes/sangue , Autoanticorpos/sangue , Biomarcadores Farmacológicos/metabolismo , Coagulação Sanguínea , Fator XIII/imunologia , Deficiência do Fator XIII/terapia , Hemorragia/terapia , Humanos , Masculino , Prognóstico , RiscoRESUMO
BACKGROUND: Factor (F)XIII deficiency is a rare inherited bleeding disorder, but can also be acquired due to the development of inhibitors. CASE REPORT: A 17-year-old female with systemic lupus erythematosus and end-stage kidney disease secondary to Class IV lupus nephritis developed spontaneous subcutaneous and muscular hematomas and delayed major bleeding after invasive procedures. She had abnormal kaolin thromboelastography (kTEG; decreased maximal amplitude, representative of clot strength) initially attributed to thrombocytopenia and uremic platelet dysfunction, but her FXIII activity was undetectable, and a high-titer antibody against FXIII was identified. She had improvement in clinical bleeding and in kaolin thromboelastogram result and transient improvement in FXIII activity after each dose of plasma-derived FXIII concentrate (Corifact) or cryoprecipitate. Her inhibitor titers gradually improved with multiple immunosuppressive therapies and plasma exchange. While her FXIII activity level remained mildly decreased, she has not had additional significant bleeding. CONCLUSION: Treatment with either plasma-derived FXIII or cryoprecipitate is an effective treatment to normalize the kTEG variables and clinical bleeding diatheses associated with acquired FXIII inhibitors. Higher doses may be needed in patients with high-titer inhibitor.
Assuntos
Autoanticorpos/imunologia , Deficiência do Fator XIII/terapia , Fator XIII/imunologia , Adolescente , Fator XIII/uso terapêutico , Deficiência do Fator XIII/etiologia , Deficiência do Fator XIII/imunologia , Feminino , Hematoma , Hemorragia/prevenção & controle , Humanos , Imunossupressores/uso terapêutico , Falência Renal Crônica , Lúpus Eritematoso Sistêmico , Troca PlasmáticaRESUMO
Autoimmune hemophilia-like disease (hemorrhaphilia) due to anti-factor XIII (FXIII) antibodies (AH13) is a very rare, life-threatening bleeding disorder. A 77-year-old woman developed macrohematuria and a right renal pelvic hematoma. The coagulation times were not prolonged, but FXIII activity and antigen levels were severely and moderately reduced to 9 and 29% of normal values, respectively. Accordingly, the FXIII-specific activity turned out to be low. FXIII inhibitor and anti-FXIII-A subunit autoantibodies were detected by a 1:1 crossmixing test and immunoblot and immunochromatographic assays. She was therefore diagnosed with "definite AH13" and treated with plasma-derived FXIII concentrates to arrest the hemorrhage. In addition to a highly compressed inferior vena cava by a huge renal pelvic hematoma, deep vein thrombosis (DVT) and pulmonary thromboembolism (PE) were identified by systemic computed tomography. The patient was immediately started on anticoagulation therapy with low-dose heparin. Emboli disappeared quickly, probably because under-crosslinked thrombi caused by severe FXIII deficiency are vulnerable to fibrinolysis. After about 1.5 years, anti-FXIII-A subunit autoantibodies still remained despite the use of rituximab, steroid pulse therapy, oral prednisolone, and oral cyclophosphamide treatments. In conclusion, an extremely rare AH13 case complicated by DVT and PE was successfully managed by balancing anticoagulation therapy with hemostatic therapy.
Assuntos
Autoanticorpos/sangue , Doenças Autoimunes/complicações , Doenças Autoimunes/terapia , Deficiência do Fator XIII/complicações , Deficiência do Fator XIII/terapia , Fator XIII/antagonistas & inibidores , Fator XIII/imunologia , Embolia Pulmonar/complicações , Idoso , Anticoagulantes/uso terapêutico , Autoanticorpos/imunologia , Doenças Autoimunes/imunologia , Ciclofosfamida/uso terapêutico , Fator XIII/uso terapêutico , Deficiência do Fator XIII/imunologia , Feminino , Hematoma/complicações , Hematoma/diagnóstico por imagem , Heparina/uso terapêutico , Humanos , Nefropatias/complicações , Nefropatias/diagnóstico por imagem , Rituximab/uso terapêutico , Trombose Venosa/complicaçõesRESUMO
INTRODUCTION: Acquired factor XIII (FXIII) deficiency due to autoantibody is a rare, severe bleeding diathesis. Its laboratory diagnosis and classification represents a difficult task. AIM: Introduction of novel approaches into the diagnosis and characterization of anti-FXIII autoantibody and demonstration of their use in the diagnosis of a patient with autoimmune FXIII deficiency. METHODS: Factor XIII activity, FXIII antigen levels and the titre of anti-FXIII-A antibody were monitored throughout the course of the disease. FXIII activity was measured by ammonia release assay; FXIII-A2 B2 complex, total and free FXIII-B concentrations were determined by ELISAs. The binding constant for the interaction of the autoantibody with recombinant FXIII-A2 (rFXIII-A2 ) and FXIII-A2 B2 was determined by surface plasmon resonance (SPR). The inhibitory capacity of IgG was expressed as the concentration exerting 50% inhibition of FXIII activation/activity (IC50). The truncation of FXIII-A by thrombin was monitored by western blotting. The inhibition of Ca2+ -induced FXIII activation and active FXIII (FXIIIa) were assessed by FXIII activity assay. RESULTS: The antibody bound to rFXIII-A2 and FXIII-A2 B2 with high affinity and accelerated the decay of supplemented FXIII concentrate. An IC50 value of 170.1 µg IgG·mL-1 indicated effective FXIII neutralization. The main neutralizing effect of the autoantibody was the inhibition of FXIIIa. After 2 months, due to combined therapeutic modalities, the autoantibody disappeared and FXIII activity significantly elevated. CONCLUSION: The anti-FXIII-A autoantibody exerted a combined effect including inhibition of FXIIIa and acceleration of FXIII decay in the plasma. IC50 and binding constant determinations added important information to the characterization of the autoantibody.
Assuntos
Autoanticorpos/imunologia , Fator XIII/imunologia , Hemorragia/diagnóstico , Hemorragia/imunologia , Subunidades Proteicas/imunologia , Idoso de 80 Anos ou mais , Suscetibilidade a Doenças , Feminino , HumanosRESUMO
: Congenital factor XIII (FXIII) deficiency is a rare bleeding disorder accompanied by a variety of bleeding events. Severely deficient patients require regular replacement therapy. With development of FXIII concentrate, the risk of viral infections transmitted by fresh frozen plasma and cryoprecipitate is diminished, but the possibility of inhibitor development remains a challenging issue in the management of these patients. The aim of this study was to assess FXIII inhibitor development in Iranian patients with FXIII deficiency (FXIIID). This study enrolled 50 (30 women and 20 men) patients with severe congenital FXIIID from southeast Iran who underwent long-term (more than 4 years or more than 50 injections) prophylaxis with FXIII concentrate (Fibrogammin P, Dade Behring, Marburg, Germany). We evaluated plasma FXIII activity and FXIII inhibitor on day 28 after the last prophylaxis administration. The method for investigation of FXIII inhibitor was based on Bethesda assay. The mean age of the study population was 13.8â±â8.3 years. The minimum and maximum FXIII activity levels were less than 1-4.5% (meanâ±âSD, 2.6â±â0.7%). Our investigations showed that all patients with severe form of FXIIID were treated without inciting inhibitor development. Despite long-term prophylaxis in the studied patients, none was found to have developed FXIII inhibitors.
Assuntos
Autoanticorpos/análise , Deficiência do Fator XIII/tratamento farmacológico , Fator XIII/imunologia , Fator XIII/uso terapêutico , Adolescente , Adulto , Autoanticorpos/efeitos adversos , Autoanticorpos/efeitos dos fármacos , Criança , Pré-Escolar , Fator XIII/efeitos adversos , Deficiência do Fator XIII/complicações , Deficiência do Fator XIII/congênito , Deficiência do Fator XIII/prevenção & controle , Feminino , Hemorragia/tratamento farmacológico , Hemorragia/prevenção & controle , Humanos , Irã (Geográfico) , Masculino , Adulto JovemRESUMO
Autoimmune acquired factor XIII (F13) deficiency or autoimmune hemophilia-like disease (hemorrhaphilia) resulted from the generation of anti-F13 antibodies (AH13) is a severe bleeding disorder that occurs mainly in the elderly. Although rare, the number of patients diagnosed with AH13 has recently increased. To improve understanding of this disease, the author summarized 93 ever reported/diagnosed AH13 cases. About 50% of cases were idiopathic. In the remaining half of the patients, autoimmune diseases and malignancies were the most common underlying diseases. Intramuscular and subcutaneous bleeding were the most frequently reported symptoms. Hemorrhage was the cause of death in 13 patients. In 4 patients, the diagnosis was established after hemorrhagic death. Therefore, physicians/hematologists must raise the awareness of AH13 as a life-threatening disease. Most patients were treated with F13 concentrates to arrest bleeding and with prednisolone and cyclophosphamide to eradicate anti-F13 autoantibodies. AH13 cases tend to become chronic and intractable and require close follow-up over an extended period.
Assuntos
Autoanticorpos/imunologia , Doenças Autoimunes/sangue , Doenças Autoimunes/imunologia , Deficiência do Fator XIII/sangue , Deficiência do Fator XIII/etiologia , Fator XIII/imunologia , Anticorpos Neutralizantes/sangue , Anticorpos Neutralizantes/imunologia , Autoanticorpos/sangue , Comorbidade , Diagnóstico Diferencial , Gerenciamento Clínico , Fator XIII/antagonistas & inibidores , Deficiência do Fator XIII/diagnóstico , Deficiência do Fator XIII/terapia , Humanos , Avaliação de Resultados em Cuidados de Saúde , Fenótipo , Prognóstico , Fatores de RiscoRESUMO
BACKGROUND: Acquired Factor (F)XIII deficiency is a very rare bleeding diathesis with a potentially fatal outcome, previously described in the context of autoimmune disorders and leukemias. There is minimal information on autoantibody characterization and the role of antifibrinolytic therapy in patient management. CASE REPORT: A 79-year-old woman with a 3-month history of bruising and heavy menorrhagia presented with ongoing vaginal bleeding, symptomatic anemia, and a right thigh hematoma. Initial management included an axillary lymph node biopsy and coagulation evaluation. Pathologic examination of the biopsy specimen revealed mantle cell lymphoma. Clot solubility assay was consistent with a FXIII activity of less than 3%. An anti-FXIII inhibitor was suspected, the epitope specificity of which was mapped by micropeptide array analysis to regions in the ß-sandwich and catalytic core domain of the FXIII-A subunit. Management with cryoprecipitate, steroids, rituximab, and antifibrinolytic therapy resolved the bleeding diathesis and suppressed the inhibitor. CONCLUSION: This is the first reported case of an acquired FXIII inhibitor associated with mantle cell lymphoma in which the epitope specificity of the pathologic autoantibody was accurately defined. Antifibrinolytic therapy played a prominent role in the prevention of bleeding complications in the window period between initiation of immunosuppression and disappearance of the pathologic anti-FXIII autoantibody.
Assuntos
Autoanticorpos , Inibidores dos Fatores de Coagulação Sanguínea , Epitopos , Deficiência do Fator XIII , Fator XIII , Linfoma de Célula do Manto , Idoso , Autoanticorpos/sangue , Autoanticorpos/imunologia , Inibidores dos Fatores de Coagulação Sanguínea/sangue , Inibidores dos Fatores de Coagulação Sanguínea/imunologia , Epitopos/sangue , Epitopos/imunologia , Fator XIII/imunologia , Fator XIII/metabolismo , Deficiência do Fator XIII/sangue , Deficiência do Fator XIII/etiologia , Deficiência do Fator XIII/imunologia , Feminino , Humanos , Linfoma de Célula do Manto/sangue , Linfoma de Célula do Manto/imunologiaAssuntos
Anticorpos Neutralizantes/sangue , Doenças Autoimunes/diagnóstico , Fator XIII/imunologia , Artéria Hepática/cirurgia , Ruptura Esplênica/diagnóstico , Idoso , Transfusão de Sangue , Embolização Terapêutica , Ensaio de Imunoadsorção Enzimática , Fator XIII/análise , Feminino , Hemorragia/etiologia , Humanos , Artéria Esplênica/diagnóstico por imagem , Ruptura Esplênica/etiologia , Ruptura Esplênica/terapia , Tomografia Computadorizada por Raios XRESUMO
INTRODUCTION: Coagulation factor XIII (FXIII) is a plasma fibrin-stabilizing factor comprising A and B subunits (FXIII-A and FXIII-B, respectively) in the form of a heterotetramer (FXIII-A2B2). A humanized monoclonal antibody to the interleukin-6 receptor (tocilizumab, TCZ) has emerged as an effective treatment for rheumatoid arthritis (RA), because it drastically reduces the inflammation of RA. We previously reported that two TCZ-treated RA patients with acquired FXIII deficiency developed pelvic hemorrhage. METHODS: Because TCZ treatment had been shown to be related to low FXIII ammonia release activity and FXIII antigen in the two RA cases, we further examined FXIII-related parameters in 36 TCZ-treated RA patients and compared to 29 healthy controls by employing functional and immunologic assays for FXIII. RESULTS: FXIII-A antigen and FXIII amine incorporation and ammonia release activities were significantly lower in the TCZ-treated group than the control group. The TCZ-treated group also showed mildly low FXIII-A2B2 and FXIII-B levels, and their fibrinogen levels were the lower limit of normal. A significant correlation between FXIII-B and fibrinogen was observed in the control and the TCZ groups, suggesting a common metabolic mechanism(s) for these two hepatic proteins. Because the specific activities of FXIII were normal and neither anti-FXIII-A nor anti-FXIII-B antibody was detected, the overall low FXIII level may have resulted from its impaired synthesis under an unbalanced cytokine milieu caused by TCZ treatment. CONCLUSION: Concomitant deficiencies in multiple hemostatic factors, including FXIII, may lead to an increased risk for hemorrhage in TCZ-treated RA patients.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Deficiência do Fator XIII/complicações , Anticorpos Monoclonais Humanizados/imunologia , Artrite Reumatoide/imunologia , Fator XIII/análise , Fator XIII/imunologia , Deficiência do Fator XIII/imunologia , Feminino , Fibrinogênio/análise , Humanos , Masculino , Receptores de Interleucina-6/imunologiaRESUMO
Autoimmune hemorrhaphilia due to anti-factor XIII (FXIII) antibodies (AH13) is a life-threatening disease associated with high risk of surgical bleeding. Since AH13 occurs mainly in the elderly, patients of AH13 tend to be complicated with other life-threatening diseases that may require surgical procedures. During our nation-wide survey on AH13, supported by the Japanese Ministry of Health, Labor, and Welfare, patients with unexplained bleeding were examined for FXIII-related parameters and anti-FXIII autoantibodies. A 64-year-old man had previously been tentatively diagnosed with AH13 and received immunosuppressive therapies, as FXIII inhibitor was detected by functional cross-mixing studies. About 2 years later, he was definitively diagnosed with AH13, because our immuno-chromatographic test and enzyme-linked immuno-sorbent assay detected FXIII-bound anti-FXIII-A subunit autoantibodies. Since routine endoscopic examination revealed suspected esophageal carcinoma, a preparatory FXIII pharmacokinetic (PK) analysis was performed by infusing FXIII concentrates prior to biopsy. Consequently, biopsy of this lesion was done without bleeding complications. One month later, a second PK study was carried out before surgery, and esophageal bypass surgery was completed successfully under FXIII replacement therapy. Our experience with this case suggests that operations can be performed safely and with confidence even in patients with such life-threatening hemorrhagic diseases.
Assuntos
Autoanticorpos/sangue , Doenças Autoimunes/imunologia , Carcinoma/cirurgia , Neoplasias Esofágicas/cirurgia , Fator XIII/administração & dosagem , Fator XIII/imunologia , Hemofilia A/etiologia , Hemofilia A/imunologia , Cuidados Pré-Operatórios , Procedimentos Cirúrgicos do Sistema Digestório/métodos , Fator XIII/farmacocinética , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
A 65-year-old woman was admitted with acute intramuscular hemorrhage of the left gluteus medius and piriformis muscles and associated anemia. Blood tests showed low plasma factor XIII (FXIII) antigen and activity. A cross-mixing test revealed a concave "inhibitor" pattern and anti-FXIII-A subunit antibody was detected. The patient was diagnosed with autoimmune hemorrhaphilia resulting from anti-FXIII antibody. The bleeding has not recurred since the initiation of treatment with oral immunosuppressive agents. Although hemorrhagic acquired FXIII deficiency is a rare disorder, prompt recognition of the underlying mechanism can save lives.
Assuntos
Autoanticorpos/sangue , Deficiência do Fator XIII/etiologia , Fator XIII/imunologia , Hemorragia/imunologia , Idoso , Feminino , Hemorragia/tratamento farmacológico , Humanos , Imunossupressores/uso terapêutico , Músculo EsqueléticoAssuntos
Algoritmos , Deficiência do Fator XIII/diagnóstico , Reação em Cadeia da Polimerase/métodos , Polimorfismo de Fragmento de Restrição , Autoanticorpos/sangue , Autoanticorpos/imunologia , Coagulação Sanguínea , Testes de Coagulação Sanguínea , Plaquetas/química , Consanguinidade , Éxons/genética , Fator XIII/análise , Fator XIII/genética , Fator XIII/imunologia , Deficiência do Fator XIII/classificação , Deficiência do Fator XIII/epidemiologia , Deficiência do Fator XIII/genética , Testes Hematológicos/economia , Humanos , Incidência , Irã (Geográfico)/epidemiologia , Mutação de Sentido Incorreto , Mutação Puntual , Reação em Cadeia da Polimerase/economia , Subunidades Proteicas/genética , SolubilidadeRESUMO
INTRODUCTION: Autoimmune haemophilia-like disease (or haemorrha-philia) due to anti-factor XIII (FXIII; F13 to avoid confusion with FVIII or FXII) antibodies (termed AH13) is a severe bleeding disorder. Although AH13 is thought to be rare, 'the number of its diagnosed patients' has recently increased in Japan. However, its prevalence remains unknown. AIM: To improve understanding of this disease, we examined and diagnosed 32 'new' Japanese patients with AH13. METHODS: The presence of antibodies against F13-A subunit and/or F13-B subunit was confirmed by using a dot blot test and enzyme-linked immunosorbent assays. RESULTS: Most of our patients had autoantibodies against the F13-A subunit (88%). A predominance of men (59%) was observed. The mean age and residual F13 activity of our AH13 cohort were 71.7 years and 10.5% of normal, respectively, and 53% of cases were idiopathic. Autoimmune disorders and malignancies were the leading underlying disease (both 16%). Intramuscular and subcutaneous bleeding were the leading symptoms (both 72%). Most of our patients were treated with F13 concentrates (72%) to arrest bleeding and with prednisolone (81%) to eradicate anti-F13 autoantibodies. Cyclophosphamide and rituximab (both 25%) were also administered. The mortality of AH13 was high (22%), and haemorrhage was the major cause of death (71%). Moreover, 13% of our AH13 patients were diagnosed after haemorrhagic death. CONCLUSION: Physicians/haematologists must raise the awareness of AH13 as a life-threatening disease. This report represents the only experience of a nationwide survey, and may contribute to a diagnosis on potentially overlooked non-Japanese AH13 patients in other countries in the world.
Assuntos
Autoanticorpos/imunologia , Doenças Autoimunes/imunologia , Fator XIII/imunologia , Hemofilia A/imunologia , Adulto , Idoso , Povo Asiático , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/tratamento farmacológico , Feminino , Hemofilia A/diagnóstico , Hemofilia A/tratamento farmacológico , Hemostáticos/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Análise de Sobrevida , Resultado do TratamentoRESUMO
Autoimmune haemorrhaphilia XIII/13 (AH13) is an acquired life-threatening bleeding disorder due to anti-factor XIII (FXIII) autoantibodies (auto-Abs). AH13 patients may die of haemorrhage without correct diagnosis and proper treatment because of lack of awareness and the absence of rapid easy-to-use tests specific for this disease. Currently, the definitive diagnosis is established by cumbersome and time-consuming laboratory tests such as dot-blot assays and enzyme-linked immunosorbent assays (ELISA), and therefore these tests are generally not carried out. To save AH13 patients' lives, there is an urgent necessity for developing a rapid test for FXIII auto-Abs. We first generated and characterised mouse monoclonal antibodies (mAb) against human FXIII A subunit (FXIII-A), and then developed a rapid immunochromatographic test (ICT) for detection of anti-FXIII-A auto-Abs using one mAb with a dissociation constant of 9.3 × 10⻹¹ M. The auto-Ab-FXIII-A complex was captured by the mAb on a nitrocellulose membrane and visualised by Au-conjugated anti-human IgG Ab. Mixing with healthy control plasma improved the detection of auto-Abs in patients having extremely low levels of FXIII-A. The specificity and sensitivity of the ICT were 87 % and 94 %, respectively. We also detected auto-Abs against activated FXIII (FXIIIa) in three patients by pre-converting FXIII to FXIIIa by thrombin treatment. ICT values were significantly inversely correlated with FXIII activity levels, indicating an association between the quantity of anti-FXIII autoantibodies and AH13. This reliable rapid ICT assay can be applied to a point-of-care test to detect anti-FXIII-A auto-Abs, and will contribute to early diagnosis and treatment of AH13.
Assuntos
Autoanticorpos/sangue , Doenças Autoimunes/diagnóstico , Cromatografia de Afinidade/métodos , Deficiência do Fator XIII/diagnóstico , Fator XIII/imunologia , Testes Imediatos , Anticorpos Monoclonais Murinos/imunologia , Especificidade de Anticorpos , Área Sob a Curva , Doenças Autoimunes/sangue , Doenças Autoimunes/imunologia , Calibragem , Estudos de Casos e Controles , Cromatografia de Afinidade/normas , Diagnóstico Precoce , Mapeamento de Epitopos , Deficiência do Fator XIII/sangue , Deficiência do Fator XIII/imunologia , Humanos , Testes Imediatos/normas , Valor Preditivo dos Testes , Curva ROC , Padrões de Referência , Reprodutibilidade dos TestesRESUMO
Although the incidence of autoimmune hemorrhaphilia due to anti-Factor XIII (FXIII, not FVIII or FXII to avoid confusion) antibodies (AH13) or hemorrhagic "acquired FXIII deficiency due to anti-FXIII autoantibodies" was previously considered rare, it has been on the increase in the twenty-first century, at least in Japan. An 83-year-old woman with an unexplained hemorrhage was admitted to our hospital for intramuscular hematoma and severe anemia. Her FXIII activity was reduced to 10 % of normal; since FXIII inhibitors and anti-FXIII-A subunit autoantibodies were detected, she was definitively diagnosed with AH13. Despite developing cardiac tamponade due to pericardial hemorrhage, she clinically recovered from AH13 after hemostatic therapy with FXIII-concentrates and immunosuppressive treatment with rituximab and cyclophosphamide. However, her FXIII activity remained low and she died of hemorrhage 3.5 years after admission. AH13 patients should be monitored for a prolonged period, as this disease is very likely a chronic intractable hemorrhagic disorder.
Assuntos
Autoanticorpos/imunologia , Doenças Autoimunes/tratamento farmacológico , Deficiência do Fator XIII/tratamento farmacológico , Fator XIII/imunologia , Hemorragia/tratamento farmacológico , Hemostáticos/uso terapêutico , Imunossupressores/uso terapêutico , Idoso de 80 Anos ou mais , Doenças Autoimunes/complicações , Doenças Autoimunes/imunologia , Doença Crônica , Ciclofosfamida/uso terapêutico , Deficiência do Fator XIII/complicações , Deficiência do Fator XIII/imunologia , Feminino , Hematoma/complicações , Hematoma/tratamento farmacológico , Hematoma/imunologia , Hemorragia/complicações , Hemorragia/imunologia , Humanos , Indução de Remissão , Rituximab/uso terapêuticoRESUMO
BACKGROUND: Autoimmune hemophilia-like disease (hemorrha-philia or hemorrhagic disorder) caused by anti-factor XIII antibodies (termed AH13) or 'autoimmune FXIII deficiency' is a life-threatening bleeding disorder. AH13 was thought to be rare worldwide. OBJECTIVES: Because the number of diagnosed AH13 cases has recently been increasing, at least in Japan, we conducted a nationwide survey supported by the Japanese Ministry of Health, Labor, and Welfare, and explored the pathologic mechanism(s) of AH13. METHODS: We diagnosed AH13 cases during the last 11 years according to the presence of anti-FXIII autoantibodies confirmed by a dot blot assay and ELISA, and characterized 33 of these both immunologically and biochemically. RESULTS: The AH13 cases were immunologically classified into three types, Aa, Ab, and B. Type Aa autoantibodies, observed in 27 cases, were directed against the native FXIII A subunit (FXIII-A), and blocked FXIII activation. The autoantibodies not only prevented assembly of new FXIII-A2 B2 heterotetramers, but also removed FXIII-A from native FXIII-A2 B2 heterotetramers by forming an FXIII-A-IgG complex. Type Ab autoantibodies, detected in three cases, preferentially bound to activated FXIII-A and inhibited its activity. Type Aa and Ab autoantibodies were 'neutralizing' FXIII antibodies (or FXIII inhibitors), and thus could be screened with functional assays. Type B antibodies, detected in two cases, were non-neutralizing anti-FXIII B subunit (FXIII-B) autoantibodies that possibly accelerated the clearance of FXIII, and thus could be diagnosed exclusively with immunologic methods. CONCLUSION: There are three major types of anti-FXIII autoantibody, with distinct targets and mechanisms that cause AH13.